TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT06386146: JAB-30355 in Patients With Advanced Solid Tumors Harboring TP53 Y220C Mutation

Sponsor: Jacobio Pharmaceuticals Co., Ltd. · Phase: PHASE1/PHASE2 · Area: ONCOLOGY · Target Enrollment: 144 pts

Competing Trials Overlap

10 Active Trials

Excess Burn Exposure

$471,240

Rescue Site Savings

+$314,160

Unlock Full NCT06386146 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06386146 Rescue Dossier →